Compare Elastic NV (ESTC) vs Moderna, Inc. (MRNA) Price & Performance

Elastic (ESTC) trades at $97.54, up 4.77% on the day, reflecting strong momentum as it approaches resistance near $98. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though the short-term RSI indicates potential overbought conditions. Fundamentally, the company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, projected to rise from $1.48 billion in 2025 to $1.8 billion in 2026, while net income is expected to swing from a loss to a $376 million profit, signaling improving profitability. Recent news highlights product innovations in AI and observability platforms, reinforcing its competitive edge.

The outlook for ESTC is positive, driven by earnings beats, solid revenue expansion, and strategic product launches in high-growth areas like AI and data search. Key risks include high valuation multiples, such as a P/E of 27.22 and EV/EBITDA of 496.59, which may limit upside if growth slows. Analyst consensus is strongly bullish with a 64.71% buy rating, though the average price target of $79.50 suggests caution relative to the current price. Investors should weigh the strong fundamental trajectory against valuation concerns and market volatility.

Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.

Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.